FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979484641> ?p ?o ?g. }

• W1979484641 endingPage "e73530" @default.
• W1979484641 startingPage "e73530" @default.
• W1979484641 abstract "Among key potential drug target proteolytic systems in the malaria parasite Plasmodium falciparum are falcipains, a family of hemoglobin-degrading cysteine proteases, and the ubiquitin proteasomal system (UPS), which has fundamental importance in cellular protein turnover. Inhibition of falcipains blocks parasite development, primarily due to inhibition of hemoglobin degradation that serves as a source of amino acids for parasite growth. Falcipains prefer P2 leucine in substrates and peptides, and their peptidyl inhibitors with leucine at the P2 position show potent antimalarial activity. The peptidyl inhibitor MG132 (Z-Leu-Leu-Leu-CHO) is a widely used proteasome inhibitor, which also has P2 leucine, and has also been shown to inhibit parasite development. However, the antimalarial targets of MG132 are unclear. We investigated whether MG132 blocks malaria parasite development by inhibiting hemoglobin degradation and/or by targeting the UPS. P. falciparum was cultured with inhibitors of the UPS (MG132, epoxomicin, and lactacystin) or falcipains (E64), and parasites were assessed for morphologies, extent of hemoglobin degradation, and accumulation of ubiquitinated proteins. MG132, like E64 and unlike epoxomicin or lactacystin, blocked parasite development, with enlargement of the food vacuole and accumulation of undegraded hemoglobin, indicating inhibition of hemoglobin degradation by MG132, most likely due to inhibition of hemoglobin-degrading falcipain cysteine proteases. Parasites cultured with epoxomicin or MG132 accumulated ubiquitinated proteins to a significantly greater extent than untreated or E64-treated parasites, indicating that MG132 inhibits the parasite UPS as well. Consistent with these findings, MG132 inhibited both cysteine protease and UPS activities present in soluble parasite extracts, and it strongly inhibited recombinant falcipains. MG132 was highly selective for inhibition of P. falciparum (IC50 0.0476 µM) compared to human peripheral blood mononuclear cells (IC50 10.8 µM). Thus, MG132 inhibits two distinct proteolytic systems in P. falciparum, and it may serve as a lead molecule for development of dual-target inhibitors of malaria parasites." @default.
• W1979484641 created "2016-06-24" @default.
• W1979484641 creator A5012724745 @default.
• W1979484641 creator A5025566908 @default.
• W1979484641 creator A5035234412 @default.
• W1979484641 creator A5036812595 @default.
• W1979484641 creator A5042244254 @default.
• W1979484641 creator A5045451244 @default.
• W1979484641 creator A5068439853 @default.
• W1979484641 creator A5077631479 @default.
• W1979484641 date "2013-09-02" @default.
• W1979484641 modified "2023-10-12" @default.
• W1979484641 title "Blocking Plasmodium falciparum Development via Dual Inhibition of Hemoglobin Degradation and the Ubiquitin Proteasome System by MG132" @default.
• W1979484641 cites W1556426431 @default.
• W1979484641 cites W1963722730 @default.
• W1979484641 cites W1969503178 @default.
• W1979484641 cites W1969894269 @default.
• W1979484641 cites W1972959613 @default.
• W1979484641 cites W1976757612 @default.
• W1979484641 cites W1977724107 @default.
• W1979484641 cites W1982525775 @default.
• W1979484641 cites W1987575637 @default.
• W1979484641 cites W1988159034 @default.
• W1979484641 cites W1988937622 @default.
• W1979484641 cites W1989593071 @default.
• W1979484641 cites W1989990175 @default.
• W1979484641 cites W1991915276 @default.
• W1979484641 cites W1991930087 @default.
• W1979484641 cites W1993545625 @default.
• W1979484641 cites W1996101488 @default.
• W1979484641 cites W1997298397 @default.
• W1979484641 cites W1999042605 @default.
• W1979484641 cites W1999119754 @default.
• W1979484641 cites W2004830871 @default.
• W1979484641 cites W2006505501 @default.
• W1979484641 cites W2010440422 @default.
• W1979484641 cites W2011716103 @default.
• W1979484641 cites W2012845953 @default.
• W1979484641 cites W2016982223 @default.
• W1979484641 cites W2018531445 @default.
• W1979484641 cites W2020251171 @default.
• W1979484641 cites W2025204393 @default.
• W1979484641 cites W2029985793 @default.
• W1979484641 cites W2031215274 @default.
• W1979484641 cites W2034037368 @default.
• W1979484641 cites W2081703573 @default.
• W1979484641 cites W2083762132 @default.
• W1979484641 cites W2084721485 @default.
• W1979484641 cites W2085187792 @default.
• W1979484641 cites W2099242689 @default.
• W1979484641 cites W2114818342 @default.
• W1979484641 cites W2121986537 @default.
• W1979484641 cites W2124583600 @default.
• W1979484641 cites W2130280297 @default.
• W1979484641 cites W2130580441 @default.
• W1979484641 cites W2131316262 @default.
• W1979484641 cites W2138841180 @default.
• W1979484641 cites W2142316927 @default.
• W1979484641 cites W2149210774 @default.
• W1979484641 cites W2151758852 @default.
• W1979484641 cites W2159831275 @default.
• W1979484641 cites W2160649586 @default.
• W1979484641 cites W2164874913 @default.
• W1979484641 cites W2165174924 @default.
• W1979484641 cites W2168360120 @default.
• W1979484641 cites W23638900 @default.
• W1979484641 cites W4248713218 @default.
• W1979484641 doi "https://doi.org/10.1371/journal.pone.0073530" @default.
• W1979484641 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3759421" @default.
• W1979484641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24023882" @default.
• W1979484641 hasPublicationYear "2013" @default.
• W1979484641 type Work @default.
• W1979484641 sameAs 1979484641 @default.
• W1979484641 citedByCount "51" @default.
• W1979484641 countsByYear W19794846412013 @default.
• W1979484641 countsByYear W19794846412014 @default.
• W1979484641 countsByYear W19794846412015 @default.
• W1979484641 countsByYear W19794846412016 @default.
• W1979484641 countsByYear W19794846412017 @default.
• W1979484641 countsByYear W19794846412018 @default.
• W1979484641 countsByYear W19794846412019 @default.
• W1979484641 countsByYear W19794846412020 @default.
• W1979484641 countsByYear W19794846412021 @default.
• W1979484641 countsByYear W19794846412022 @default.
• W1979484641 countsByYear W19794846412023 @default.
• W1979484641 crossrefType "journal-article" @default.
• W1979484641 hasAuthorship W1979484641A5012724745 @default.
• W1979484641 hasAuthorship W1979484641A5025566908 @default.
• W1979484641 hasAuthorship W1979484641A5035234412 @default.
• W1979484641 hasAuthorship W1979484641A5036812595 @default.
• W1979484641 hasAuthorship W1979484641A5042244254 @default.
• W1979484641 hasAuthorship W1979484641A5045451244 @default.
• W1979484641 hasAuthorship W1979484641A5068439853 @default.
• W1979484641 hasAuthorship W1979484641A5077631479 @default.
• W1979484641 hasBestOaLocation W19794846411 @default.
• W1979484641 hasConcept C104317684 @default.
• W1979484641 hasConcept C181199279 @default.
• W1979484641 hasConcept C182220744 @default.

• next